GPC1 CAR-T / REPROCELL - LARVOL DELTA

Structure-guided protein engineering and humanization of GPC1-targeted nanobody CAR T cells for treating pancreatic cancer (AACR 2026) - "Humanized constructs with the highest humanness scores, geometry, and similarity scores were back-mutated to preserve critical residues in the nanobody framework sequences and were then evaluated for GPC1 binding affinity and cell-surface binding. Using this AI-assisted, structure-guided strategy, we aim to generate clinically suitable humanized VHH nanobody scaffolds for GPC1 CAR T therapy and other nanobody-based clinical applications."

CAR T-Cell Therapy • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CD8 • GPC1